Calcitriol

1. What conditions has Calcitriol been studied for?

• Neurodegenerative diseases

  • Alzheimer’s disease (AD): discussed as potentially neuroprotective and linked to low vitamin D status in epidemiology; calcitriol is produced in the brain and acts via VDRs.

  • Parkinson’s disease (PD): tested in an animal model (rotenone-induced PD in rats) with mechanistic endpoints (neuroinflammation, autophagy, Sirt1/NF-κB pathway).

• Post-thyroidectomy hypocalcemia

  • Evaluated as routine oral supplementation (with calcium) versus selective supplementation guided by parathyroid hormone testing (cost-utility model).

• Chronic kidney disease (CKD) and related outcomes

  • Reviewed in the context of progressive calcitriol and vitamin D deficiency in CKD, impaired VDR activation, and associations with disease progression and mortality.

• Cancers (primarily mechanistic/preclinical and observational links)

  • Breast cancer: preclinical and clinical literature on calcitriol as an anticancer agent and as an adjuvant with antineoplastic drugs; mechanistic work in ER+ breast cancer (aromatase/estrogen signaling, COX-2/PG pathways) and effects on cancer-associated fibroblasts (CAFs) ex vivo.

  • Colorectal cancer (CRC): vitamin D deficiency is frequently associated with CRC incidence/mortality in observational studies; mechanistic studies emphasize actions of active vitamin D metabolite (calcitriol).

• Metabolic/weight-related outcomes

  • Body weight and adiposity outcomes: assessed in a systematic review and individual participant data (IPD) meta-analysis of randomized placebo-controlled calcitriol trials across groups including obesity, type 2 diabetes, type 1 diabetes, postmenopausal women, and CKD (excluding dialysis and cancer).

• Alcohol/ethanol-related liver injury (preclinical)

  • Hepatocyte protection in ethanol-induced injury models (cell-based): effects on apoptosis, oxidative stress, mitochondrial dysfunction, and autophagy/mitophagy markers.

• Cardiovascular outcomes (reviewed)

  • Vitamin D/calcitriol discussed for pleiotropic cardiovascular effects in a literature review (details not fully shown in the provided abstract excerpt).

2. Does it work in treating those conditions? Summarize the evidence.

• Post-thyroidectomy hypocalcemia: Evidence in the provided abstract supports practical benefit and cost-effectiveness of routine supplementation (calcium + calcitriol) versus selective supplementation.

  • In a Markov cost-utility model, routine supplementation cost less ($102 vs $164) and produced slightly higher QALYs (0.95936 vs 0.95725), translating to population-level savings of $29,365/QALY (CI reported as negative values indicating cost-saving).

  • Limitation: this is a decision-analytic model, not a direct randomized clinical outcomes trial; results depend on assumptions (e.g., hypocalcemia rates, utility values, and lab testing costs).

• Parkinson’s disease (PD): In a rotenone-induced rat model, calcitriol showed neuroprotective/restorative effects.

  • Improved behavioral impairments and dopaminergic neuron depletion.

  • Reduced neuroinflammation and improved autophagy dysfunction, with up-regulation of Sirt1 and LC3 and down-regulation of P62 and NF-κB.

  • Limitation: animal model; does not establish clinical efficacy in humans with PD.

• Alzheimer’s disease (AD): The abstract describes plausible mechanisms and epidemiologic association between low vitamin D and AD risk, and proposes calcitriol neuroprotective actions (oxidative stress, neuroinflammation, Aβ clearance, autophagy, etc.).

  • However, the provided text is a review/mechanistic rationale and does not present clinical trial outcomes demonstrating that calcitriol treats or prevents AD.

• Body weight/obesity-related outcomes: Best available evidence in the provided abstracts suggests no meaningful effect on weight or body composition.

  • An IPD meta-analysis (411 participants; median follow-up 11 months; 17,084 person-months) found calcitriol did not change body weight, BMI, waist circumference, fat mass, or lean body mass versus placebo; adjustment for age/sex did not change results.

  • Limitation: authors note uncertainty remains about whether calcitriol could lower weight in vitamin D–sufficient people with obesity.

• CKD and mortality/progression: The CKD abstract emphasizes that calcitriol and vitamin D deficiency worsen with CKD and are associated with progression and death, and argues that “safe correction” is a high priority.

  • However, in the provided excerpt this is primarily pathophysiology + association and a call for trials/markers, rather than definitive evidence that calcitriol supplementation improves hard outcomes (mortality, CV events, CKD progression).

• Cancer (breast, colorectal): The abstracts provide strong mechanistic and preclinical support and some discussion of clinical combination approaches, but do not establish a standard effective regimen.

  • Breast cancer: calcitriol inhibits malignant cell growth via cell cycle arrest, apoptosis, and reduced invasion/metastasis/angiogenesis; in ER+ disease it may reduce COX-2/prostaglandins, aromatase expression, and ERα signaling (in vitro/in vivo in mice).

  • Breast CAF study: ex vivo calcitriol altered CAF gene/protein expression in complex ways; conditioned media from some calcitriol-treated CAFs decreased migration of MCF-7 cells.

  • Limitation: much of this is preclinical/ex vivo; one review explicitly notes that an adjuvant regimen “has not yet been fully established.”

• Ethanol-induced hepatocyte injury: In cell-based experiments, calcitriol pretreatment improved viability and mitochondrial function and increased autophagy/mitophagy markers (LC3B-II, ATG5, p62 degradation; colocalization of autophagosomes with mitochondria).

  • Limitation: in vitro/preclinical; not evidence of clinical benefit in alcohol-related liver disease.

3. What health benefits does it have?

• Endocrine and mineral metabolism (core physiology): Calcitriol is described as the active vitamin D hormone regulating calcium/phosphorous balance and bone mineralization, acting through vitamin D receptors (VDRs) distributed across many tissues.

• Immunomodulatory and anti-inflammatory actions: Multiple abstracts describe calcitriol as immunomodulatory and anti-inflammatory; in the PD rat model it reduced neuroinflammation (e.g., down-regulated NF-κB), and in ER+ breast cancer mechanisms include suppression of COX-2 and inflammatory prostaglandins.

• Neuroprotective mechanisms (primarily mechanistic/preclinical)

  • AD-focused review: proposed benefits include mitigating oxidative stress and neuroinflammation, promoting Aβ clearance, myelin formation, neurogenesis, neurotransmission, and autophagy.

  • PD rat model: improved motor behavior and dopaminergic neuron preservation, linked to Sirt1/NF-κB and autophagy markers (LC3, p62).

• Potential anticancer actions (mostly preclinical)

  • Breast cancer: inhibits proliferation and promotes differentiation/apoptosis; may reduce invasion/metastasis/angiogenesis; may reduce estrogen synthesis/signaling in ER+ disease via aromatase and ERα down-regulation.

  • Tumor microenvironment: ex vivo calcitriol shifted some CAF outputs in directions that could reduce tumor cell migration (e.g., decreased migration of MCF-7 with conditioned media in certain patient subgroups), though effects were described as complex and mixed.

  • CRC: observational association between vitamin D deficiency and CRC incidence/mortality is noted; mechanistic studies implicate active vitamin D metabolite actions (calcitriol), but clinical benefit is not established in the provided text.

• Supportive perioperative benefit: After thyroidectomy, routine calcium + calcitriol supplementation was modeled as improving patient utility and reducing costs compared with selective supplementation.

• Cellular stress resilience (preclinical): In ethanol-injured hepatocytes, calcitriol improved mitochondrial morphology/membrane potential, reduced apoptosis/oxidative stress, and enhanced autophagy/mitophagy markers.

4. Does it have any downsides or side effects?

• Not detailed in the provided abstracts: The excerpts do not list adverse event rates or specific side effects from clinical trials.

• Mechanism-based risks are plausible but not quantified here: Because calcitriol is the active hormone regulating calcium/phosphate, a key practical concern (not addressed with data in these abstracts) is that excessive dosing can raise calcium and/or phosphate levels. The thyroidectomy abstract focuses on preventing hypocalcemia, but does not report hypercalcemia risk.

• CKD context implies a narrow therapeutic window: The CKD review emphasizes “safe correction” of calcitriol/vitamin D deficiency, indirectly suggesting that dosing and monitoring matter in CKD; however, specific harms and frequencies are not provided in the excerpt.

• Cancer microenvironment effects may be mixed: The CAF study concludes calcitriol’s effects on CAF gene/protein expression are “complex,” with both potentially anticancer and potentially procancer shifts (e.g., decreases in CCL2/TNC/MMPs vs increases in PDPN/TIMP1/SPP1). This is not a clinical side effect, but it is a potential biological downside/uncertainty relevant to oncology translation.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report specific pharmacogenomic findings (e.g., outcomes stratified by VDR polymorphisms, CYP27B1/CYP24A1 variants, or other vitamin D pathway genes), nor do they identify genotypes predicting benefit or harm from calcitriol.

• What is suggested mechanistically: Multiple abstracts emphasize that calcitriol acts through the vitamin D receptor (VDR) and that impaired VDR activation is central in CKD-related pathology. This implies that genetic variation affecting VDR function or calcitriol metabolism could matter, but no genotype-specific evidence is provided here.

• Bottom line based on these abstracts: No evidence in the supplied text supports recommending calcitriol specifically for—or avoiding it in—any particular genetic subgroup.

References

1. Physiology of Vitamin D-Focusing on Disease Prevention.
   Sunil J Wimalawansa (2024) - Nutrients
2. Role of Calcitriol and Vitamin D Receptor (
   Soon Pyo Jeong, Niti Sharma, Seong Soo A An (2024) - International journal of molecular sciences
3. Physiological Basis for Using Vitamin D to Improve Health.
   Sunil J Wimalawansa (2023) - Biomedicines
4. Mechanisms of action of vitamin D in colon cancer.
   Gemma Ferrer-Mayorga, María Jesús Larriba, Piero Crespo, Alberto Muñoz (2019) - The Journal of steroid biochemistry and molecular biology
5. Vitamin D status and cardiovascular outcome.
   F Saponaro, C Marcocci, R Zucchi (2019) - Journal of endocrinological investigation
6. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation.
   Adriana S Dusso (2011) - Kidney international supplements
7. Neuroprotective and therapeutic effects of calcitriol in rotenone-induced Parkinson's disease rat model.
   Alshimaa Magdy, Eman A E Farrag, Shereen Mohamed Hamed, Zienab Abdallah, Eman Mohamad El Nashar, Mansour Abdullah Alghamdi, Amira A H Ali, Marwa Abd El-Kader (2022) - Frontiers in cellular neuroscience
8. To supplement or not to supplement: a cost-utility analysis of calcium and vitamin D repletion in patients after thyroidectomy.
   Tracy S Wang, Kevin Cheung, Sanziana A Roman, Julie Ann Sosa (2011) - Annals of surgical oncology
9. Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update.
   Mariana Segovia-Mendoza, Janice García-Quiroz, Lorenza Díaz, Rocío García-Becerra (2021) - International journal of molecular sciences
10. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer.
    Aruna V Krishnan, Srilatha Swami, David Feldman (2012) - Steroids
11. Dual effect of vitamin D
    Natalia Łabędź, Artur Anisiewicz, Martyna Stachowicz-Suhs, Joanna Banach, Dagmara Kłopotowska, Adam Maciejczyk, Patrycja Gazińska, Aleksandra Piotrowska, Piotr Dzięgiel, Rafał Matkowski, Joanna Wietrzyk (2024) - BMC cancer
12. The effect of active vitamin D supplementation on body weight and composition: A meta-analysis of individual participant data.
    Sabrina M Oussaada, Isis Akkermans, Sandeep Chohan, Jacqueline Limpens, Jos W R Twisk, Christiane Winkler, Janaka Karalliedde, J Christopher Gallagher, Johannes A Romijn, Mireille J Serlie, Kasper W Ter Horst (2024) - Clinical nutrition (Edinburgh, Scotland)
13. Calcitriol alleviates ethanol-induced hepatotoxicity via AMPK/mTOR-mediated autophagy.
    Fang Yuan, Yingying Xu, Kai You, Jiaye Zhang, Fan Yang, Yin-Xiong Li (2021) - Archives of biochemistry and biophysics
14. Potential Molecular Mechanisms of the Anti-cancer Activity of Vitamin D.
    Dorota Skrajnowska, Barbara Bobrowska-Korczak (2019) - Anticancer research
15. Calcitriol Suppresses Warburg Effect and Cell Growth in Human Colorectal Cancer Cells.
    Chun-Yin Huang, Yu-Ting Weng, Po-Chen Li, Nien-Tsu Hsieh, Chun-I Li, Hsiao-Sheng Liu, Ming-Fen Lee (2021) - Life (Basel, Switzerland)
16. Vitamin B1 and calcitriol enhance glibenclamide suppression of diabetic nephropathy: Role of HMGB1/TLR4/NF-κB/TNF-α/Nrf2/α-SMA trajectories.
    Ibtisam Ahmed ElKhooly, Hany M El-Bassossy, Heba Osama Mohammed, Ahmed M Atwa, Noura A Hassan (2024) - Life sciences
17. Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells.
    Leyla Kavandi, Michael A Collier, Huyen Nguyen, Viqar Syed (2012) - Journal of cellular biochemistry
18. Non-classical Vitamin D Actions for Renal Protection.
    Adriana S Dusso, Kevin T Bauerle, Carlos Bernal-Mizrachi (2021) - Frontiers in medicine
19. The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD.
    Chien-Lin Lu, Dong-Feng Yeih, Yi-Chou Hou, Guey-Mei Jow, Zong-Yu Li, Wen-Chih Liu, Cai-Mei Zheng, Yuh-Feng Lin, Jia-Fwu Shyu, Remy Chen, Chung-Yu Huang, Kuo-Cheng Lu (2018) - Nutrients
20. Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer.
    Jean Schneider, Ye Won Jeon, Young Jin Suh, Seung Taek Lim (2022) - International journal of molecular sciences